Target Price consensus revisions : last 18 months |
|
|
Evolution of the average Target Price on ABBVIE |
|
|
Assessed data source © 2019 S&P Global Market Intelligence
|
|
|
AstraZeneca shares rise on early U.S. approval for leukaemia drug |
Mean consensus |
OUTPERFORM |
Number of Analysts |
12 |
Average target price |
95,18 $ |
Last Close Price |
86,44 $ |
Spread / Highest target |
50,4% |
Spread / Average Target |
10,1% |
Spread / Lowest Target |
-6,29% |
Consensus revision (last 18 months)
|